We are focused on the development of high-quality products and services that drive novel discovery and contribute to improving human health. We are also scientists that use the Oncomine® Platform to generate results. Here is a sampling of our published abstracts and posters.


  1. Rapid drug target ranking system for drug discovery: A systematic analysis of cancer genomic data from the Oncomine® Knowledgebase identifies an oncogenic role for the NFE2L2 pathway in multiple cancer types
    Sean Eddy, Mary Ellen Urick, Mark Tomilo, Armand Bankhead, Dan Rhodes, and Emma Bowden
    AACR Annual Meeting, 5–9 APR, 2014, San Diego, CA, USA
    View poster

  2. A survey of 1,000s of tumor exomes and transcriptomes to expand clinical opportunities for crizotinib
    Emma T. Bowden, Sean F. Eddy, Paul D. Williams, Nickolay A. Khazanov, Armand Bankhead III, Dinesh Cyanam, Mary Ellen Urick, Suprabhath Reddy Gajjala, Mark Tomilo, Peter J. Wyngaard, Daniel R. Rhodes
    ASCO Annual Meeting, MAY 31–JUN 4, 2013, Chicago, IL, USA
    View poster

  3. Expanded clinical opportunities for crizotinib identified from an analysis of over 5,000 patient exomes
    Sean Eddy, Mark Tomilo, Mary Ellen Urick, Armand Bankhead, Nickolay Khazanov, Dinesh Cyanam, Paul Williams, Supra Gajjala, Peter Wyngaard, Emma Bowden, and Dan Rhodes
    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 19–23 NOV, 2013, Boston, MA, USA
    View poster

  4. Discovery and characterization of driver MAPK and PI3K pathway mutations in tumors and association with drug response in cell lines
    Mark Tomilo, Paul D. Williams, Emma T. Bowden, Supra R. Gajjala, Santhoshi Bandla, Sean F. Eddy, Seth E. Sadis, Peter J. Wyngaard, Nickolay A. Khazanov, Daniel R. Rhodes
    AACR Annual Meeting, 5–10 APR, 2013, Washington, DC, USA
    View poster

  5. High-throughput, systematic analysis of paired-end next-generation sequencing data to characterize the gene fusion landscape in cancer
    Seth E. Sadis, Nickolay A. Khazanov, Armand Bankhead III, Dinesh Cyanam, Paul D. Williams, Sean F. Eddy, Peter J. Wyngaard, Daniel R. Rhodes
    AACR Annual Meeting, 5–10 APR, 2013, Washington, DC, USA
    View poster

  6. Evaluating predictive drug biomarkers across 31,000+ cancer samples
    Ross Patterson, Sarah Anstead, Rachel Dull, Chris Gates, Becky Steck, Mark Tomilo, Peter Wyngaard, Daniel Rhodes
    ISCB Great Lakes Bioinformatics Conference, 15–17 MAY, 2012, Ann Arbor, MI, USA
    View poster

  7. Discovery of novel cancer genes through application of clinical metadata ontology
    Jeff Bonevich, Rachel Dull, Chris Gates, Becky Steck, Mark Tomilo, Peter Wyngaard, Daniel Rhodes
    San Antonio Breast Cancer Symposium, 6–10 DEC, 2011, San Antonio, TX, USA
    View poster

  8. OncoPredictor: High copy number gain of ERBB2 occurs in 1% of lung cancer patients and predicts sensitivity to lapatinib in lung cancer cell lines.
    Sean F. Eddy, Mark Tomilo, Seth Sadis, Paul D. Williams, Peter Wyngaard, Daniel R. Rhodes
    AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, 12–16 NOV, 2011, San Francisco, CA, USA
    View poster

  9. Focal amplification of existing kinase inhibitor targets identified from TCGA data and integrative analysis.
    Daniel R. Rhodes, Matthew A. Anstett, Paul D. Williams, Peter Wyngaard.
    Keystone Symposia: Changing Landscape of the Cancer Genome, 25 JUN, 2011, Boston, MA, USA
    View poster

  10. Breast cancer gene expression modules: A platform for companion diagnostics development.
    Scott A. Tomlins, Seth Sadis, Daniel R. Rhodes
    ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, 18–20 OCT, 2010, Hollywood, FL, USA
    View poster

  11. OncoPredictor: An integrative genomics platform to systematically predict responsive tumor populations from in vitro drug response data.
    Daniel Rhodes, Gary Daubresse, Peter Wyngaard, Mark Tomilo, Paul Williams, Christine O'Day, Yulia Ovechkina, Usha Warrior, Seth Sadis
    AACR Translational Cancer Medicine USA, 11–14 JUL, 2010, San Francisco, CA, USA
    View poster

  12. Integrated analysis of patient level genetic aberrations in human cancer.
    Chris Gates, Matt Anstett, Supra Gajjala, Peter Wyngaard, Daniel Rhodes.
    AACR Translation of the Cancer Genome, 15–18 OCT, 2011, San Francisco, CA, USA
    View poster

  13. Somatic mutations in human cancer cell lines predict sorafenib response.
    Daniel R. Rhodes, Scott H. Kaufmann, Xue Wei Meng, Peter Wyngaard, Judith S. Leopold
    AACR Translational Cancer Medicine, 21–24 MAR, 2010, Amsterdam, The Netherlands

  14. Gene expression modules associated with cetuximab response in metastatic colorectal cancer predict additional patient populations likely to respond.
    Daniel R. Rhodes, Wendy Lockwood Banka, Arul M. Chinnaiyan
    AACR Translation of the Cancer Genome, 7–10 FEB, 2009, Boston, MA, USA
    View poster

  15. Meta-analysis of outlier expression profiles in breast cancer identifies AGTR1 overexpression as an opportunity for targeted therapy.
    Daniel R. Rhodes, Scott A. Tomlins, Rohit Mehra, Qi Cao, Bharathi Laxman, Shanker Kalyana-Sundaram, Lei Wang, Beth E. Helgeson, Peter C. Lucas, Celina G. Kleer, Daniel F. Hayes, Sooryanarayana Varambally, Arul M. Chinnaiyan
    AACR Annual Meeting, 12–16 APR, 2008, San Diego, CA, USA
    View poster